STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy

(2018) Haiyan Jia et al.   THROMBOSIS RESEARCH

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

(2018) Adriana Albini et al.   Frontiers in Immunology

Efficacy and Toxic Effects of Cancer Immunotherapy Combinations—A Double-Edged Sword

(2018) Chad Tang et al.   JAMA Oncology

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

Rationale for stimulator of interferon genes–targeted cancer immunotherapy

(2017) Thaiz Rivera Vargas et al.   EUROPEAN JOURNAL OF CANCER

CD4 + T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?

(2017) Michele De Palma et al.   IMMUNITY

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

(2017) Lin Tian et al.   NATURE

Tumour ischaemia by interferon-γ resembles physiological blood vessel regression

(2017) Thomas Kammertoens et al.   NATURE

STING expression and response to treatment with STING ligands in premalignant and malignant disease

(2017) Jason R. Baird et al.   PLoS One

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity

(2017) Casey R. Ager et al.   Cancer Immunology Research

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

(2017) Jeremy B. Foote et al.   Cancer Immunology Research

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment

(2016) Jin-Sung Park et al.   CANCER CELL

A Milestone Review on How Macrophages Affect Tumor Growth

(2016) Christophe Caux et al.   CANCER RESEARCH

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

Dual Faces of IFN  in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity

(2016) M. Mandai et al.   CLINICAL CANCER RESEARCH

Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

(2016) Qi Chen et al.   NATURE IMMUNOLOGY

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors

(2015) J. R. Baird et al.   CANCER RESEARCH

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer

(2015) L. Corrales et al.   CLINICAL CANCER RESEARCH

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

(2015) Olivier Demaria et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

(2015) Juan Fu et al.   Science Translational Medicine

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment

(2015) Thomas F. Gajewski   SEMINARS IN ONCOLOGY

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

T Lymphocyte–Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity

(2015) Christopher V. Carman et al.   Frontiers in Immunology

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption

(2014) Chan Kim et al.   CANCER CELL

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

Activated STING in a Vascular and Pulmonary Syndrome

(2014) Yin Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment

(2014) T. Ohkuri et al.   Cancer Immunology Research

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis

(2011) H. Zheng et al.   BLOOD

IFN-  Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity

(2011) S. Terawaki et al.   JOURNAL OF IMMUNOLOGY

Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer

(2011) Hanseul Yang et al.   Molecular Cancer

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

(2008) Hiroki Ishikawa et al.   NATURE